PHASE 1/2 STUDY: FRONTLINE BRENTUXIMAB VEDOTIN plus AVD IN PEDIATRIC PTS WITH ADVANCED HODGKIN LYMPHOMA

被引：0
|
作者：
Franklin, Anna [1 ]
Zecca, Marco [1 ]
Fagioli, Franca [1 ]
Luisi, Flavio Augusto [1 ]
Song, Gregory [1 ]
Suri, Ajit [1 ]
Leonard, E. Jane [1 ]
Locatelli, Franco [1 ]
机构：
[1] Childrens Hosp Colorado, Aurora, CO USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
106
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Nivolumab Outperforms Brentuximab Vedotin in Newly Diagnosed Advanced Hodgkin Lymphoma
    O'Brien, Susan
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 359 - 359
  • [42] Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma
    Nikolaenko, Liana
    Nademanee, Auayporn
    FUTURE ONCOLOGY, 2020, 16 (29) : 2273 - 2282
  • [43] Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma
    Connors, Joseph M.
    Ansell, Stephen M.
    Fanale, Michelle
    Park, Steven I.
    Younes, Anas
    BLOOD, 2017, 130 (11) : 1375 - 1377
  • [44] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2017, 130
  • [45] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13
  • [46] Real-World Study Evaluating the Efficacy of Frontline Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Patients with Hodgkin Lymphoma: A Retrospective Analysis
    Cai, Qingqing
    Xia, Yi
    Liu, Panpan
    Zhang, Yuchen
    Zou, Qihua
    Cai, Jun
    BLOOD, 2022, 140 : 12035 - 12036
  • [47] BRENTUXIMAB VEDOTIN PLUS VIGEPP CHEMOTHERAPY FOR RELAPSED/REFRACTORY ADOLESCENT HODGKIN LYMPHOMA
    Tsaplina, N.
    Valiev, T.
    LEUKEMIA RESEARCH, 2022, 121 : S60 - S60
  • [48] Brentuximab vedotin plus AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort
    Bowers, Jackson
    Anna, Jacob
    Bair, Steven Michael
    Annunzio, Kaitlin
    Epperla, Narendranath
    Pullukkara, Jerrin Joy
    Gaballa, Sameh
    Spinner, Michael
    Li, Shuning
    Messmer, Marcus
    Nguyen, Joseph
    Ayers, Emily C.
    Wagner, Charlotte Burton
    Hu, Boyu
    Di, Mengyang
    Huntington, Scott F.
    Furqan, Fateeha
    Shah, Nirav Niranjan
    Chen, Christina
    Svoboda, Jakub
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study
    Forero-Torres, Andres
    Holkova, Beata
    Sharman, Jeff P.
    Friedberg, Jonathan W.
    Berkowitz, Maurice J.
    Fintel, William
    Chen, Robert
    Boccia, Ralph V.
    Saleh, Mansoor
    Josephson, Neil
    Palanca-Wessels, Maria Corinna
    Yasenchak, Christopher A.
    BLOOD, 2014, 124 (21)
  • [50] Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant
    Steiner, Raphael Eric
    Becnel, Melody R.
    Cuglievan, Branko
    Nair, Ranjit
    Singh, Prachee
    Strati, Paolo
    Jain, Preetesh
    Ahmed, Sairah
    Samaniego, Felipe
    Gunther, Jillian R.
    Pinnix, Chelsea C.
    Fang, Penny
    Dabaja, Bouthaina S.
    Feng, Lei
    Lee, Hun Ju
    BLOOD, 2020, 136
12345